ELEVATION ONCOLOGY INC's ticker is ELEV and the CUSIP is 28623U101. A total of 41 filers reported holding ELEVATION ONCOLOGY INC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $7,654,257 | -47.4% | 2,834,910 | 0.0% | 3.31% | -32.7% |
| Q1 2024 | $14,543,088 | +855.3% | 2,834,910 | 0.0% | 4.92% | +984.1% |
| Q4 2023 | $1,522,347 | -19.0% | 2,834,910 | 0.0% | 0.45% | -41.3% |
| Q3 2023 | $1,878,411 | -56.4% | 2,834,910 | 0.0% | 0.77% | -63.3% |
| Q2 2023 | $4,309,063 | -20.0% | 2,834,910 | 0.0% | 2.11% | -18.6% |
| Q1 2023 | $5,386,329 | +100.0% | 2,834,910 | 0.0% | 2.59% | +45.8% |
| Q4 2022 | $2,693,165 | -15.9% | 2,834,910 | 0.0% | 1.78% | -16.4% |
| Q3 2022 | $3,203,000 | -19.3% | 2,834,910 | 0.0% | 2.13% | -24.9% |
| Q2 2022 | $3,969,000 | -44.4% | 2,834,910 | 0.0% | 2.83% | -26.5% |
| Q1 2022 | $7,144,000 | -58.1% | 2,834,910 | 0.0% | 3.86% | -36.0% |
| Q4 2021 | $17,066,000 | -22.7% | 2,834,910 | 0.0% | 6.02% | +36.7% |
| Q3 2021 | $22,084,000 | -42.6% | 2,834,910 | 0.0% | 4.40% | -28.5% |
| Q2 2021 | $38,470,000 | – | 2,834,910 | – | 6.16% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 2,834,910 | $7,654,257 | 3.31% |
| venBio Partners LLC | 2,434,255 | $6,572,489 | 2.84% |
| Velan Capital Investment Management LP | 597,299 | $1,612,707 | 0.92% |
| Exome Asset Management LLC | 369,322 | $997,170 | 0.87% |
| Logos Global Management LP | 3,850,000 | $10,395,000 | 0.84% |
| TANG CAPITAL MANAGEMENT LLC | 3,060,000 | $8,262,000 | 0.84% |
| Palo Alto Investors LP | 1,800,106 | $4,860,286 | 0.56% |
| Darwin Global Management, Ltd. | 1,916,290 | $4,809,888 | 0.56% |
| Ghost Tree Capital, LLC | 600,000 | $1,620,000 | 0.51% |
| Affinity Asset Advisors, LLC | 1,468,825 | $3,965,828 | 0.46% |